Asset profile
AR1001
Small molecule
Evidence outlook · registrational
Alzheimer's Disease: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. The registry's posted readout date (2026-05) has passed without a status update. Check News for topline announcements.
NCT03625622: The study was randomized, quadruple-masked, and placebo-controlled, with 210 participants, and used clinical cognitive and global-change measures (ADAS-Cog 13 and ADCS-CGIC) as primary endpoints. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The overall-population primary endpoint showed no significant differences (published qualitatively); the numeric improvement shown is a post-hoc monotherapy subgroup analysis.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
64 competitors in this universe: 0 direct rivals (same mechanism and indication), 4 same-class, 60 same-indication; 6 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| AR1001: this drug | Phase 3 | Small molecule | PDE5 | ||
| Sildenafil (Revatio) | Phase 3 | Small molecule | PDE5 | ||
| Tadalafil (Adcirca) | Phase 3 | Small molecule | PDE5 | ||
| Udenafil (Zydena) | Phase 3 | Small molecule | PDE5 | ||
| RTN-001 | Phase 2 | Small molecule | PDE5 | ||
| Benzgalantamine (Zunveyl) | Approved | Small molecule | Acetylcholinesterase/nicotinic receptor (prodrug) | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Dextromethorphan / Bupropion (Auvelity) | Approved | Small molecule | sigma-1/NMDA | ||
| Donanemab (Kisunla) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Lecanemab (Leqembi) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Xanomeline / Trospium Chloride (Cobenfy) | Approved | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | ||
| ACP-204 | Phase 3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | ||
| Bezisterim | Phase 3 | Small molecule | ERK/NF-kB inflammatory | ||
| Blarcamesine | Phase 3 | Small molecule | Sigma-1 receptor / muscarinic receptor (dual) | ||
| Buntanetap | Phase 3 | Small molecule | APP/tau/alpha-synuclein/TDP-43 (translation) | ||
| Cerebrolysin | Phase 3 | Peptide | Multi-target (ginsenoside) |
…and 49 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.